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Aim Right ventricular pacing (VP)hasbeenhypothesized to increase the risk in heart failure (HF) and atrial fibrillation (AF). The
ANSWER study evaluated, whether an AAI-DDD changeover mode to minimize VP (SafeR) improves outcome com-
pared with DDD in a general dual-chamber pacemaker population.
Methods
and results
ANSWER was a randomized controlled multicentre trial assessing SafeR vs. standard DDD in sinus node disease (SND) or AV
block (AVB) patients. After a 1-month run-in period, they were randomized (1 : 1) and followed for 3 years. Pre-specified
co-primary end-points were VP and the composite of hospitalization for HF, AF, or cardioversion. Pre-specified secondary
end-points were cardiac death or HF hospitalizations and cardiovascular hospitalizations. ANSWER enrolled 650 patients
(52.0% SND, 48% AVB) at 43 European centres and randomized in SafeR (n¼ 314) or DDD (n¼ 318). The SafeR mode
showed a significant decrease in VP compared with DDD (11.5 vs. 93.6%, P, 0.0001 at 3 years). Deaths and syncope did
not differ between randomization arms. No significant difference between groups [HR¼ 0.78; 95% CI (0.48–1.25);
P¼ 0.30] was found in the time to event of the co-primary composite of hospitalization for HF, AF, or cardioversion, nor in
the individual components. SafeR showed a 51% risk reduction (RR) in experiencing cardiac death or HF hospitalization
[HR¼ 0.49; 95% CI (0.27–0.90); P¼ 0.02] and 30% RR in experiencing cardiovascular hospitalizations [HR¼ 0.70; 95%
CI (0.49–1.00); P¼ 0.05].
Conclusion SafeR safely and significantly reduced VP in a general pacemaker population though had no effect on hospitalization for
HF, AF, or cardioversion, when compared with DDD.
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Introduction
The risk in experiencing adverse cardiac outcomes due to ventricular
pacing (VP) with dual-chamber pacemakers is well established. Ven-
tricular pacing modifies left ventricular (LV) contraction by generat-
ing an electrical activation sequence resembling a left bundle branch
block. The resulting dyssynchrony is associated with LV remodelling,1
reduced ejection fraction (EF),2,3 and increased risk in heart failure
(HF) anddeath inpatientswith alreadydepressedLVEF.4 Asecondary
analysis from the mode selection trial (MOST) established the hy-
pothesis that also pacemaker patients with preserved LVEF may
develop HF depending on the prevalence of right VP.5 Accordingly,
a number of different pacing algorithms have been developed that
reduce the degree of VP in the atrio-ventricular (AV) sequential
pacing mode (DDD). Such systems have been shown in clinical
studies to reduce the risk in developing atrial fibrillation (AF),
mainly in patients with sinus node disease (SND).6,7
The SafeR algorithm (Sorin CRM, Clamart, France) was developed
to individually adapt to a patient’s varying AV conduction and to
combine the benefits of single-chamber atrial pacing (AAI) with the
safety of DDD pacing. Several randomized trials have previously
confirmed the efficient VP prevention and safety of the algorithm in
selected populations.8– 10 In the SaveR study, SafeR reduced VP
over 1 year in selected patients with preserved or minimally impaired
AV conduction compared with DDD.11 However, in patients with
conventional indication to pacemaker, including AV block (AVB),
long-term data on the impact of SafeR on the risk in developing
adverse cardiac outcomes, including developing HF or AF, is undeter-
mined.
The evaluAtioN of the SafeR mode in patients With a dual-
chambER pacemaker indication (ANSWER, ClinicalTrials.gov Identi-
fier: NCT00562107) has been designed to assess the efficacy, safety,
and benefits of the use of the SafeR mode, in unselected patients with
an indication for a dual-chamber pacemaker compared with standard
DDD pacing, without minimized VP.
Methods
Study design
The ANSWER study was an investigator-initiated, prospective, rando-
mized, single-blind, controlled, parallel-design, European, multicentre
(43 centres) trial. Patients aged ≥18 years were included if they had a
pacemaker indication and had received a dual-chamber pacemaker
equipped with the SafeR mode less than a month prior to enrolment.
The pacemaker indication was based on the diagnosis of SND, second
degree intermittent AVB, or third degree intermittent or permanent
AVB.12 Patients were excluded if they had permanent AF, sustained ven-
tricular arrhythmias, congenital complete heart block, or vasovagal
syncope. The study was conducted in accordance with the declaration
of Helsinki13 and Good Clinical Practice. The protocol was approved
by the local ethics committees.
Devices implanted and randomization
SafeR-enabled pacemakers were used (Symphony 2550 device or REPLY
DR, Sorin CRM SAS). The SafeR dual-chamber pacemaker mode has
been designed to privilege intrinsic AV activation, while continuously
monitoring spontaneous AV conductionanddelivering rightVPonly tem-
porarily, and only in case of demonstrated lasting long PR or repetitively
lacking intrinsic ventricular activation. This changeover pacing mode
commutes between single-chamberatrial (AAI) pacing anddual-chamber
pacing (DDD) and has previously been described in detail.8 –10 The selec-
tion of atrial (bipolar configuration required) and right VP leads was left to
the implanters’ discretion. All devices implanted were CE marked at the
beginning of the study.
At implant, all pacemakers were programmed to SafeR for 1 month.
Subsequently, patients were randomized in a 1 : 1 fashion to the SafeR
mode (SafeR group) or to a conventional dual-chamber pacing mode
(DDD) with a nominal AV delay (155 ms after a sensed atrial event,
220 ms after a paced atrial event, dynamic shortening with increasing
heart rate) as preferred settings (control group).
Follow-up and study end-points
Follow-up visits were scheduled after enrolment before hospital
discharge, at 1 month (randomization visit), at 6, 12, 18, 24, and
36 months (termination visit). At each visit, the device memory was
interrogated.
ANSWER had a co-primary technical end-point, the percentage of VP
at 1 year, and a co-primary clinical end-point, a composite of hospitaliza-
tion for HF, AF, or cardioversion at 3 years. Pre-specified secondary
end-points comprised thepercentageofVPat 3 years, the individual com-
ponents of the co-primary composite end-point, hospitalization for HF
or cardiac death, and CV hospitalization (defined as hospitalization for
major cardiovascular event, HF, AF, cardioversion, ventricular tachycar-
dia, and cardiac death, occurring at hospital). The comparison of the
hospital stay during these cardiovascular hospitalizations was performed
as an ancillary analysis.
Collection and adjudication of adverse events
The assessment relied on the site investigators notification of any serious
adverse event (AE) and all device-related AE. The site investigators were
supported in the detection of events by study monitors. All these events
were reported on specific AE forms and had to be transferred to
the study manager as soon as possible and no later than five working
days after detection. The AE forms included information on the time
course, symptoms, treatment modalities, and diagnosis. All events
were blindly reviewed and categorized by the Study Steering Committee
during regular meetings. The events, including deaths, were adjudicated
and classified as serious (Y/N), protocol-related (Y/N), device-related
(Y/N), procedure-related (Y/N), hospitalization (Y/N), AF-related
(Y/N), HF-related (Y/N), cardioversion (Y/N), other cardiovascular
event (Y/N), clinical (non-cardiovascular) event (Y/N), syncope (Y/N). In
syncope patients with unclear clinical presentation, the device memory
was also reviewed with the aim to identify a correlation with asystolic
pauses during AAI-DDD commutations, and to check for possible ven-
tricular tachyarrhythmias induced by changeover episodes. If deemed
necessary, additional information was requested from the study sites.
Data on percentage of VP were ascertained from device memories.
Changes of the programming mode, retrieved from case report forms
and implant files, were also reviewed by the Steering Committee.
Sample size and statistical methods
The trial was designed to detect the effects for both co-primary end-
points. The sample size calculation was thus based on the 1-year
assumed rate of VP and the 3-years expected incidence of the composite
of hospitalization for HF, AF, or cardioversion. Under the assumption of
(i) per cent of VP of 30.7% in the control group and 7.1% in the SafeR
group, with a common standard deviation of 34%; (ii) frequency of the
composite end-point of 20% in the control group and 10% in the SafeR
group, corresponding to a difference of 10%; With a statistical power
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of 90% and a type 1 error of 0.025 (two-sided), we estimated the sample
size to 45 and 532 patients in total, respectively, for the cumulative per
cent of VP (co-primary technical end-point at 1 year) and for hospitaliza-
tion for HF, AF, or cardioversion (co-primary composite end-point at 3
year). Therefore, the sizing was based on the sample size of 532 patients.
The rate of loss to follow-up was estimated at 20%, and we therefore
planned to enroll 640 patients in total.
The co-primary technical end-point on the percentage of VP was cal-
culated on the intention-to-treat (ITT) population with at least one
implant file; and analysed using the Last Observation Carried Forward
imputation method. The number of patients with missing data for
whom the last observation needed to be carried forward is reported.
The co-primary composite end-point was analysed based on a Kaplan–
Meier analysis, with patients dropping out censored at the time of their
last observation.ABonferroni correctionwasapplied toboth co-primary
end-points and a P-value of 0.025 was set as the significance limit for both
co-primary end-points. Each of the co-primary end-points had to be
significant at the 0.025 level in order to reach the primary end-point.
All secondary end-points were carried out on the ITT population
and considered statistically significant at a P-value of 0.05. All of them
though were considered exploratory.
The co-primary technical end-point on the percentage of VP was ana-
lysed by the Mann–Whitney U-test. The co-primary composite end-
point (hospitalization for HF, AF, and cardioversion) was analysed by
Kaplan–Meier curves and rates per 100 person/year for description,
log-rank test for comparisons, Cox model with calculation of hazard
ratio (HR) and 95% CI for quantifying the effect. The risk reduction
(RR) is reported when significant.
Secondary end-points time-to event were analysed by Kaplan–Meier
curves, which accounts for censoring, and rates per 100 person/year for
description, log-rank test for comparisons, Cox model with calculation of
HR and 95% CI for quantifying the effect. The end-point of the duration of
hospitalization for cardiovascular event was analysed using a 0 inflated
negative binomial regression.
For non-normally distributed data, median values and inter-quartile
ranges are shown except for the duration of hospitalization for which
median values and inter-quartile ranges are presented for hospitalization
duration.0 dayand number (percentage) of patients free from hospital-
ization is reported.
For categorical data, number and percentage are presented. Safety
categorical data were compared with the x2 test or Fisher’s exact test
when appropriate.
All statistical analyses were performed with the SASTM statistical soft-
ware, version 9.2.
Results
Study population
A total of 650 patients were included in the study at 43 European
centres (Austria, France, Germany, Italy, Slovakia, Spain, Switzerland)
from 7 December 2007 to 10 March 2010 (83% received a REPLY
DR and 17% a Symphony 2550). A total of 632 patients were rando-
mized: 314 to the SafeR group and 318 to the DDD group. A total of
18 patients were not randomized for the following reasons: death
(n ¼ 2), consent refusal or withdrawal (n ¼ 6), did not meet the in-
clusion criteria (n ¼ 4), lost-to-follow-up (n ¼ 2), atrial rhythm dis-
orders (n ¼ 2), did not attend the M1 visit in due time (n ¼ 2).
Patient characteristics are shown in Table 1. Approximately half
of the population had sick SND (52%) or AVB (48%); 6% had perman-
ent AVB and 42% had intermittent AVB.
The patient flow is shown in Figure 1. A total of 473 patients com-
pleted the 36 months follow-up (last visit performed on 17 May
2013). During follow-up, 38 patients (11.9%) out of the DDD
group were reprogrammed to SafeR and 13 patients (4.1%) were
reprogrammed to VVI; out of the SafeR group 23 patients (7.3%)
were reprogrammed to DDD and 8 patients (2.5%) to VVI(R). The
average duration of follow-up was 919+ 342 days from implant.
Five hundred and fifty eight patients participated in the analysis
of the co-primary end-point of VP, and in 163 out of them the last
observation had to be carried forward.
Study outcome
The median (Q1; Q3) prevalence of VP was significantly reduced in
the SafeR group vs. DDD at 1 year [4.8%, (Q1–Q3: 0.1–72.0) vs.
95.4%, (Q1–Q3: 53.8–99.4), P, 0.0001], which difference
remained substantially unaltered at 3 years [11.5%, (Q1–Q3: 0.1–
73.8) vs. 93.6%, (Q1–Q3: 62.3–99.2), P, 0.0001]. The risk in
experiencing a hospitalization for HF, AF, or cardioversion did not
significantly differ between randomization groups (HR ¼ 0.78; 95%
CI: 0.48–1.25; P ¼ 0.30; Figure 2A).
Likewiseboth individual componentsof the co-primary composite
end-point showed no significant difference between randomization
arms, although for the HF component a numerical reduction
tended to favour SafeR (hospitalization for HF: HR ¼ 0.58; 95% CI:
0.31–1.09; P ¼ 0.09; Figure 2B; hospitalization for AF or cardiover-
sion: HR ¼ 1.09; 95% CI: 0.56–2.09; P ¼ 0.80; Figure 2C).
A significant RR of 51% was observed for the combined secondary
end-point of cardiac death or HF hospitalization in the SafeR group
compared with DDD (HR¼ 0.49; 95% CI: 0.27–0.90; P ¼ 0.02;
Figure 3A). Similarly, a 30% RR for the secondary end-point of cardio-
vascular hospitalization was reported in the SafeR group compared
with DDD (HR¼ 0.70; 95% CI: 0.49–1.00; P ¼ 0.05; Figure 3B). The
median (Q1; Q3) duration of cardiovascular hospitalization for patients
with .0 day of hospitalization was shorter in the SafeR vs. the DDD
group [5.0 (2.0; 11.0) vs. 6.0 (2.0; 17.0)]; more patients were free
from a cardiovascular hospitalization in SafeR vs. DDD [260 (82.8%)
vs. 245 (77.0%)] (0 inflated negative binomial regression, P ¼ 0.03).
Safety
No differences in the occurrence of death and device- or procedure-
related events were observed between treatment groups (Table 2).
None of the syncopal events reported was considered device-
related, and no pro-arrhythmic effects of changeover episodes
were documented.
Discussion
ANSWER investigated VP prevention and long-term clinical out-
comes of an AAI–DDD changeover mode designed to minimize
VP (SafeRTM) in a typical patient population indicated to conventional
cardiac pacing, as shown by an equal proportion of included patients
presenting with either SND and/or AVB. The study met the
co-primary technical end-point; it showed that VP was significantly
reduced in patients with SND, and—for the first time—it reported
that in intermittent AVB VP was reduced as well, whereas the algo-
rithm safely provided mandatory VP in those with permanent AVB.
Importantly, the percentage of VP increased over time, which reflects
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progressive AV conduction disease. In contrast, the co-primary clin-
ical end-point, representedbyacombinationofhospitalization forHF
or AF or cardioversion, did not significantly differ between the ran-
domization groups, nor were the individual end-point components
significantly different in the DDD vs. SafeR group.
Dual-chamber pacing implies a trade-off between the paced res-
toration of a reasonable heart rate and undesired pacing-induced
cardiac dyssynchrony. But it is sometimes difficult to decide, when
pacing is actually required, and when it is more appropriate to
avoid pacing. This is particularly true for patients with intermittent
AVB and in those with a prolonged PR interval. In these patients,
re-establishing a favourable AV sequence by VP with best possible
transmitral LV filling may be offset by pacing-induced LV impairment;
and vice versa, preserving prolonged intrinsic AV conduction may
prevent pacing-related dyssynchrony, but may in turn produce
undesirably fused transmitral filling.
A secondary analysis of a large pacemaker study to compare DDD
vs. VVI in SND14 founded the hypothesis that VP favours clinical HF
despite a fairly preserved LVEF.5 Another smaller randomized study2
showed that in SND with normal AV conduction DDD with short or
long AV delay was associated with more AF compared with AAI. The
impairment of LV haemodynamics by right VP15 was hypothesized to
be responsible for the observed adverse effects. Modifiers of right VP
adverse effects can likely be seen in the global LV systolic function and
the presence of an unpaced bundle branch block (BBB). Patients with
depressed LVEF may particularly be harmed by pacing-induced dys-
synchrony and require biventricular pacing in case of AVB,4,16
whereas those with BBB and already compromised electro-
mechanical activation may experience less of a disadvantage by
right VP.17–19
Several large studies, conducted in highly selected populations,
investigated the effect (AF-related and HF-related outcome) of
different device-based pacing strategies to prevent VP.6,20 – 22
The SAVEPACe study,6 conducted in patients with SND and pre-
served intrinsic AV conduction, evaluated a mixture of VP preven-
tion programming compared with DDD with a high percentage of
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Table 1 Baseline characteristics of the study population
Clinical characteristics Enrolled (n 5 650) SafeR group (n5 314) DDD group (n 5 318)
Age, mean+ SD, years 72.4+11.2 71.8+12.2 72.9+9.8
Male gender, n (%) 358 (55.2) 182 (58.0) 169 (53.1)
Heart disease, n (%)
Coronary artery disease (%) 183 (28.2) 87 (27.7) 91 (28.6)
Dilated cardiomyopathy (%) 31 (4.8) 15 (4.8) 13 (4.1)
Valvular disease (%) 84 (12.9) 37 (11.8) 44 (13.8)
Comorbidities, n (%)
Arterial hypertension 423 (65.1) 197 (62.7) 215 (67.6)
COPD 32 (4.9) 13 (4.1) 17 (5.3)
Diabetes 140 (21.5) 68 (21.7) 68 (21.4)
Indications for implant, n (%)
Sinus node disease 336 (52.0) 167 (53.5) 160 (50.5)
AV block 310 (48.0) 145 (46.5) 157 (49.5)
Intermittent AV block 270 (41.8) 127 (40.7) 136 (42.9)
Permanent AV block 40 (6.2) 18 (5.8) 21 (6.6)
Symptoms of HF
None, n (%) 202 (32.0) 103 (33.7) 91 (29.4)
NYHA I/II/III/IV, % 43.0/50.7/5.8/0.5 41.9/53.7/3.9/0.5 44.5/48.6/6.4/0.5
LVEF, mean+ SD, % 58.3+8.7 58.6+9.1 58.2+8.3
ECG parameters
LBBB, n (%) 64 (11.1) 29 (10.4) 31 (11.1)
LAHB, n (%) 52 (8.7) 29 (9.9) 23 (7.9)
LPHB, n (%) 1 (0.2) 1 (0.4) 0 (0)
AR, mean+ SD, ms 214.0+58.2 207.1+55.9 219.8+60.2
PRa, mean+ SD, ms 191.4+45.2 189.6+47.1 191.8+43.6
Arrhythmias history, n (%)
Atrial arrhythmiasb 248 (38.2) 116 (37.1) 125 (39.3)
Ventricular arrhythmias 16 (2.5) 2 (0.6) 13 (4.1)
AR, atrial-paced—ventricle-sensed interval; AV block, atrio-ventricular block; COPD, chronic obstructive pulmonary disease; HF, heart failure; LAHB, left anterior hemi-block; LBBB,
left bundle branchblock; LPHB, left posterior hemi-block; LVEF, left ventricular ejection fraction determined by echocardiography; NYHA, New York Heart Association; SD, standard
deviation; PR, atrial–sensed—ventricle-sensed interval.
aDetermined on SND and AVBI patients only.
bAtrial fibrillation, flutter, or tachycardia.
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Figure 1 CONSORT flow diagram.
Figure 2 (A) Freedom from hospitalization for heart failure, atrial fibrillation or cardioversion. (B) Freedom from hospitalization for heart failure.
(C ) Freedom from hospitalization for atrial fibrillation or cardioversion.
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VP; it demonstrated a prolonged time to persistent AF by VP pre-
vention. In contrast, three recently published large pacemaker
trials20 – 22 fell short of confirming a significant clinical advantage
through VP prevention. The DANPACE trial20 randomized 1415
SND patients to AAIR vs. DDDR and adapted the AV programming
in the DDDR group to the baseline PR interval. This trial showed
no differences in mortality or HF and a disadvantage of AAIR vs.
DDDR in paroxysmal AF. The PREFER-MVP study21 randomized
605 patients without permanent AVB after pulse generator replace-
ment to VP prevention by the managed ventricular pacing (MVP)
mode, vs. DDD. This trial failed to demonstrate a difference in
cardiovascular hospitalizations over 2 years. In a similar manner,
MINERVA22 study which enrolled patients with bradycardia
(mainly with SND and previous atrial tachyarrhythmias) and
compared DDDR with the MVP mode with and without preventive
atrial pacing algorithms (DDDRP), demonstrated successful pre-
vention of permanent AF by DDDRP in this specific population,
but showed no effect of VP prevention on AF progression, death,
or cardiovascular hospitalization. Thus, findings of the ANSWER
study are well in line with those of most recent trials that
appear to collectively contradict the earlier SAVEPACe results6
with regard to the AF end-point. It must be kept in mind,
however, that SAVEPACe demonstrated a prolonged time to per-
sistent AF by VP prevention, but did not either show a difference
in AF-related hospitalizations, HF, or death. When comparing
these trials, the heterogeneous end-points, different VP prevention
methods, and importantly different study populations must be
considered.
Figure 3 (A) Freedom from hospitalization for heart failure or cardiac death. (B) Freedom from cardiovascular hospitalization.
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Table 2 Number of patients with death, device, or procedure-related events and syncope
Overall (n5 650) BR (n 5 18) SafeR (n5 314) DDD (n 5 318) P-value
Deaths (%)
All causes death 58 (8.9) 2 (0.3) 26 (8.3) 30 (9.4) 0.61
Cardiac death 17 (2.6) 1 (0.2) 5 (1.6) 11 (3.5) 0.14
Device or procedure-related adverse events (%)
All device or procedure-related events 28 (4.3) 14 (2.1) 6 (1.9) 8 (2.5) 0.61
Lead dislodgment 10 (1.5) 6 (0.9) 0 4 (1.3) 0.12
Lead fracture 1 (0.2) 0 0 1 (0.3) 1.00
Pocket hematoma 4 (0.6) 4 (0.6) 0 0 -
Pocket infection 7 (1.1) 3 (0.5) 2 (0.6) 2 (0.6) 1.00
Pocket erosion 1 (0.2) 0 1 (0.3%) 0 0.50
Pacing mode intolerance 5 (0.8) 2 (0.3) 3 (1.0) 1 (0.3) 0.37
Syncope
Syncope 16 (2.5) 2 (0.3) 5 (1.6) 9 (2.8) 0.42
Results are presented as number of patients (% of patients).
A same patient could experience an event before and after randomization.
BR, before randomization.
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The ANSWER study further expands current knowledge because
it included AVB patients (6% even with complete permanent AVB)
who have not been previously considered. The SafeR changeover
mode has safely been applied to a broader pacemaker population
indicated for conventional pacing. No pro-arrhythmic adverse
effects of SafeR have been observed, whereas the induction of ven-
tricular tachycardia has been described as a rare side-effect of the
AAI-to-DDD commutation pattern used by the MVP mode.23,24 All-
cause mortality, cardiac mortality, and syncope were not significantly
different between SafeR and DDD, but deaths and syncopal events
occurred numerically less frequently in the SafeR group, which sup-
ports the view that this pacemaker mode is safe.
Interestingly, the components of the ANSWER co-primary com-
posite end-point appeared to come out differently, despite both
being non-significant. The survival curves for the AF end-point
were superimposed, whereas the HF component showed a trend
favouring SafeR. The favourable effect of SafeR-mediated VP preven-
tion on HF outcomes, however, warrants further investigation, as the
combined clinical secondary outcome of cardiac death or HF hospi-
talization differed in favour of the SafeR group, and a borderline sig-
nificant reduction in cardiovascular hospitalizations and shorter
duration of hospital stay for these hospitalizations was observed.
Additional favourable effects of the demonstrated VP prevention
in AVB patients are the possibly diminished need for biventricular
pacing in those with paroxysmal AVB (but otherwise normal PR)
and reduced LVEF;25 and improved device longevity by reduced
energy consumption.26
Study limitations
The ANSWER study and the co-primary clinical end-point have been
designed in 2006–07 based on available knowledge, before the het-
erogeneous SAVEPACe6 and DANPACE21 results had been pub-
lished. The pacemaker memory stores paced and sensed events,
but the extent of fused or pseudo-fused pacing, which is likely to
be unequal in both randomization groups, cannot be retrieved
from the counters. One-fifth of the ANSWER population had
LBBB or other types of BBB. This may have extenuated the effects
of VP prevention. The occurrence of the primary end-point was
lower than predicted by the sample size calculation, which limits
the statistical power. Because ANSWER study was a single-blinded
study, a possible influence, yet likely marginal, of the investigators’
knowledge of the treatment arm on clinical end-point components
cannot be ruled out with certainty. Although many of the cardiac
deaths in the study occurred in the hospital following an HF hospital-
ization, it must be said that the classification of causes of death is
generally associated with significant uncertainty.
Conclusions
The SafeR pacemaker mode significantly reduced VP compared with
DDDin abroad population clinically indicated to dual-chamberpace-
maker, regardless of the primary electrical disease (SND or AVB).
The risk in experiencing hospitalization for HF or AF orcardioversion
was not significantly reduced by SafeRvs. DDD. Secondaryend-point
results warrant further investigation of SafeR-mediated prevention
of HF.
Supplementary material
Supplementary material is available at European Heart Journal online.
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